Inactive Instrument

Press Releases Gracell Biotechnologies Inc.

Equities

GRCL

US38406L1035

Press Releases

Unlock all the news: Be the first to know and act before the market!

Gracell Biotechnologies Acquisition Completed	Feb. 22	GL
Gracell Biotechnologies Announces Shareholders Approval of Merger Agreement	Feb. 21	AQ
Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement	Feb. 20	GL
Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement	Feb. 20	AQ
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma	Jan. 29	GL
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma	Jan. 29	AQ
Gracell Biotechnologies : Investor Frequently Asked Questions, dated December 29, 2023 - Form 6-K	Jan. 02	PU
GRACELL BIOTECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Gracell Biotechnologies Inc. - GRCL	Dec. 31	BU
Gracell Biotechnologies : VOTING AND SUPPORT AGREEMENT - Form 6-K	Dec. 26	PU
GRCL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Gracell Biotechnologies Inc. Is Fair to Shareholders	Dec. 26	BU
Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases	Dec. 26	GL
Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases	Dec. 26	AQ
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus	Dec. 21	GL
Gracell Biotechnologies : ASH 2023 Oral Presentation - Updated Results of a Phase I Open-Label Single-Arm Study of Dual Targeting BCMA and CD19 Fastcar-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma	Dec. 12	PU
Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023	Dec. 11	GL
Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023	Dec. 11	AQ
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus	Nov. 27	GL
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus	Nov. 27	AQ
Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit	Nov. 16	GL
Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update	Nov. 13	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Gracell Biotechnologies Inc.

Equities

GRCL

US38406L1035

Press Releases

Filters